Inhaled insulin in pregnancy: A case series supporting feasibility and clinical potential for pregnant people with diabetes

Abstract Background Dose conversions, dose titration, and efficacy of inhaled insulin (TI) compared to rapid‐acting insulin (RAA) have not been studied in pregnancy. This case series demonstrates the various management approaches of TI use in pregnant patients with preexisting diabetes. Minimal data are available on the use of TI in pregnancy. Given the scarcity of data in pregnancy, our objective was to describe approaches of TI use in diabetes management during pregnancy. Research design and methods Case series. Results This case series demonstrates the versatility of TI use in pregnancy, including routine meal coverage, postprandial hyperglycemia corrections, and as a feasible alternative to RAA when compliance or consistency of use with subcutaneous injections is a challenge. In this limited case series, TI appears to be a safe alternative to RAA in pregnancy. Conclusions TI appears to be a feasible and acceptable alternative to RAA in pregnancy.